Balance Sheet
Includes Current Assets, Liabilities and Stockholder's Equity
Latest Financial Results
Q2 2021
Quarter Ended Jun 30, 2021
$3.1M
Revenue for the three and six months ended June 30, 2021 was $3.1 million and $3.5 million, respectively, compared to $0.5 million and $1.3 million for the same periods in 2020.
$50.5M
As of June 30, 2021, Adaptimmune had cash and cash equivalents of $50.5 million and Total Liquidity1 of $285.4 million.
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2020
Report Links
For complete information regarding our financials, see our periodic filings